Longeveron soars on FDA's 'RMAT' tag for Alzheimer's therapy

Longeveron

10/07/2024 15:29

(Updates)
    ** Cell therapy developer Longeveron's  LGVN.O  shares rise
~78.6% to $5.12, its highest since March
    ** Company says U.S. FDA has granted Regenerative Medicine
Advanced Therapy (RMAT) designation to its mild Alzheimer's
therapy Lomecel-B
    ** RMAT designation expedites development and review of
regenerative medicine therapies and offers sponsor companies
early interactions with FDA
    ** Including session's move, stock down 61.9% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))